Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1994-1-7
|
pubmed:abstractText |
The contents of urokinase-type plasminogen activator were estimated in superficial bladder cancer from 42 patients undergoing transurethral resection for the first time. Tumor recurred in 11 of 16 patients (68.8%) with high urokinase-type plasminogen activator content (8 ng. urokinase-type plasminogen activator per mg. protein and more) and in 12 of 26 (46.2%) with low urokinase-type plasminogen activator content. In the high content group 8 patients (50%) had disease progression compared to 2 (7.7%) in the low content group (p < 0.01). The progression rates in the high urokinase-type plasminogen activator group with stage pTa disease or tumors more than 1 cm. large were significantly higher than those in the low urokinase-type plasminogen activator group (p < 0.05). The recurrence and progression rates in the high content group with stage pT1, grades 2 and 3, single and multiple tumors, and tumors less than 1 cm. large were higher than those in the low content group. The progression-free survival rate in the high content group was significantly lower than that in the low content group (p < 0.005). In conclusion, urokinase-type plasminogen activator content may be a useful marker to predict recurrence and progression of superficial bladder cancer.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0022-5347
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
151
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
16-9; discussion 19-20
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:8254803-Aged,
pubmed-meshheading:8254803-Aged, 80 and over,
pubmed-meshheading:8254803-Carcinoma, Transitional Cell,
pubmed-meshheading:8254803-Humans,
pubmed-meshheading:8254803-Middle Aged,
pubmed-meshheading:8254803-Neoplasm Recurrence, Local,
pubmed-meshheading:8254803-Neoplasm Staging,
pubmed-meshheading:8254803-Prognosis,
pubmed-meshheading:8254803-Survival Rate,
pubmed-meshheading:8254803-Urinary Bladder Neoplasms,
pubmed-meshheading:8254803-Urokinase-Type Plasminogen Activator
|
pubmed:year |
1994
|
pubmed:articleTitle |
The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer.
|
pubmed:affiliation |
Department of Urology, Miyazaki Medical College, Japan.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|